Binding and signaling proteins based on Escherichia coli alkaline phosphatase (AP; EC 3.1.3.1) were designed for the detection of antibodies. Hybrid proteins were constructed by using wild-type AP and point mutants of AP [Asp-101 -> Ser (DlOlS) and Asp-153 -> Gly (D153G)]. The binding function of the hybrid proteins is provided by a peptide epitope inserted between amino acids 407 and 408 in AP. Binding of anti-epitope antibodies to the hybrid proteins modulates the enzyme activity of the hybrids; upon antibody binding, enzyme activity can increase to as much as 300%o of the level of activity in the absence of antibody or can decrease as much as 40%, depending on the presence or absence of the point mutations in AP. The fact that modulation is altered from inhibition to activation by single amino acid changes in the active site of AP suggests that the mechanism for modulation is due to structural alterations upon antibody binding. Modulation is a general phenomenon. The properties of the system are demonstrated by using two epitopes, one from the V3 loop of human immunodeficiency virus type 1 gpl20 protein and one from hepatitis C virus core protein, and corresponding monoclonal antibodies. The trend of modulation is consistent for all hybrids; those in wild-type AP are inhibited by antibody, while those in the AP mutants are activated by antibody. This demonstrates that modulation of enzyme activity of the AP-epitope hybrid proteins is not specific to either a particular epitope sequence or a particular antibody-epitope combination.
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Regulation of enzyme activity by binding a factor, small molecule, or protein is common (signal transduction, allosteric enzymes). While systems of this type are abundant in nature, construction of an artificial system presents a challenge; the surface of the enzyme must be modified to create a binding site for another protein, yet at the same time the catalytic activity of the enzyme must be maintained. In addition, the binding event must result in structural changes that alter the catalytic activity of the engineered enzyme.
Here, we report a molecular sensor system based on the regulation of the enzyme activity of genetically engineered Escherichia coli alkaline phosphatase (AP; EC 3.1.3.1). A known linear peptide epitope sequence is introduced onto the surface of AP in a defined location, thus creating a binding site for an antibody. We show that the enzymatic activity of such a hybrid enzyme is reduced or increased upon binding of an antibody specific for the epitope. The direction of activity change depends on the presence or absence of point mutations in the vicinity of the AP active site.
AP is a nonspecific phosphomonoesterase with a high catalytic turnover number (kcat In previous work (7), we documented an example of inhibition of the enzymatic activity of a hybrid AP that contains an insert of 13 aa from the V3 loop of human immunodeficiency virus type 1 (HIV 1) gpl20 upon binding of an anti-gpl20 monoclonal antibody (mAb). The epitope was inserted at the gene level between aa 407 and 408 in AP. The enzymatic activity of this hybrid protein, API1, is inhibited 40-50% when the anti-gpl20 mAb binds to the inserted peptide (7). Here, we find that the introduction of the point mutations DlOlS and D153G into API1 results in a shift from inhibition of enzyme activity upon antibody binding to an increase in activity upon antibody binding. This change from inhibition to activation, caused by single amino acid changes in AP, is consistent with a mechanism of modulation based on structural alteration.
To determine the general nature of modulation of APepitope hybrid proteins, a 15-aa peptide epitope from the hepatitis C virus (HCV) core protein (aa 50-64 in the core) (8) was inserted between aa 407 and 408 in wild-type AP and the DiOlS and D153G AP mutants. In the presence of several anti-HCV core mAbs, a consistent pattern of modulation is observed. The hybrid protein with the HCV epitope in wildtype AP is inhibited by the mAbs, whereas the hybrid proteins containing the DlOlS and D153G point mutations are activated by the mAbs. These results demonstrate that modulation by antibodies is not specific to a particular amino acid sequence inserted into AP nor is it specific to a particular epitopeantibody combination. The consistent pattern of inhibition or activation, depending on the AP background of the hybrid protein, suggests there may be a common mechanism for inhibition and a common mechanism for activation.
MATERIALS AND METHODS
Plasmid Constructions. The AP-epitope hybrid proteins were generated by modifying plasmids that contain a synthetic The following peptides were used for peptide competition experiments. HIV-1 gpl20 peptide (244010; Ile-Arg-Ile-GlnArg-Gly-Pro-Gly-Arg-Ala-Phe-Val-Thr-Ile-Gly-Lys) was obtained from American Biotechnologies. An HCV peptide (Gln-Pro-Arg-Gly-Arg-Arg-Gln-Pro-11e-Pro) was provided by K. Jaffe (Abbott), and a nonspecific (NS) peptide (Arg-TyrSer-Val-Ile-Leu-Leu-Asp-Thr-Leu-Leu-Gly-Arg-Met-Leu) was provided by T. Leung (Abbott). The 8; Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-ArgGln-Pro) was inserted between aa 407 and 408 in wild-type AP and in the AP mutants DiOlS and D153G to generate API2, D1O1S-12, and D153G-12, respectively.
Six anti-HCV core mAbs were tested for modulation of API2, D101S-12, and D153G-12 enzyme activity ( Table 2 ). The antibodies have no effect on the enzyme activity of wild-type AP, DiOlS, and D153G (with the exception of a 20% activation of D153G by antibody 14-153-462 (Table 3) . Anti-core mAb 14-188-104 and mAb 14-726-217 have similar affinity for D153G-12 (Kd = 0.8-1.0 x 10-6 M). The difference in the level of modulation with these mAbs is likely due to differences in the fraction of active protein (Table 3 ). In contrast, mAb 14-1287-252 has a lower affinity for D153G-I2 (Kd = 5.5 x 10-6 M) but a greater fraction of it is active (87%). The difference in the level of modulation for mAbs 14-726-217 and 14-1287-252 is likely due to the difference in binding affinity and not the difference in fraction of active protein.
The specificity of modulation of the HCV core hybrid proteins was determined by using peptide competition and an antibody not specific for the epitope insert. A peptide corresponding to amino acids 57-64 in HCV core (Gln-Pro-ArgGly-Arg-Arg-Gln-Pro-Ile-Pro) was used as a competitor of antibody modulation. Fig. 2 shows the results for mAb 14-726-217 with wild-type AP, API2, D1O1S-12, and D153G-I2. The peptide has no effect on the enzyme activity of the hybrid proteins in the absence of the anti-core mAb. The addition of peptide to API2, D1O1S-12, or D153G-I2 blocks modulation of enzyme activity in the presence of the mAb. Modulation of the HCV hybrid proteins by the other five anti-HCV core mAbs of the hybrid proteins is also blocked by the presence of the peptide (data not shown). In addition, modulation of API2, D1O1S-12, or D153G-12 is specific to antibodies against the inserted epitope; the anti-gpl20 mAb has no effect on their enzyme activities (Fig. 2) .
Properties of AP-Epitope Hybrid Proteins. Table 4 lists the AP-epitope hybrid proteins that were constructed, the kinetic constants, and temperature half-lives for the proteins. The Km values are similar for all the proteins. The presence of the point mutations DiOlS and D153G in wild-type AP has a large effect on kcat; both increase the rate of substrate turnover almost 5-fold. The introduction of these point mutations into API1 results in increased kcat values for DiOlS-I1 (1.8-fold) and D153G-I1 (1.5-fold) relative to API1, but the kcat values are approximately one-half those of the DiOlS and D153G mutants. The HCV epitope inserted into wild-type AP (API2) slightly reduces kcat. The introduction of the DiOlS point mutation into API2 results in a 2.5-fold increase in the kcat of D1O1S-I2 relative to API2; however, the kcat of D1O1S-12 is only one-third that of the DlOlS mutant. D153G-I2, which contains the D153G point mutation in API2, has a k value that is the same as API2 but only one-eighth that of D153G.
The thermal stability of the AP hybrid proteins is an indication of their relative structural stability. The stabilities of (5 nM) were assayed in the absence and presence of anti-core antibody (35 nM). Enzyme activity is expressed relative to the activity of the hybrid protein in absence of antibody. Enzyme activity values shown in boldface type differ from no antibody controls by more than 15%. An activity value <1.0 indicates inhibition of enzyme activity; a value >1.0 indicates activation of enzyme activity.
Data represent the mean of three determinations from one experiment. ND, not determined. wild-type, DiOlS, and DiOlS-Il are similar (til2 = 69-71°C).
The mutations in D153G and APIl both destabilize the proteins, lowering the tl2 values to 53°C and 58°C, respectively.
The combination of D153G and API1 to create D153G-I1 further destabilizes the protein structure (til2 = 39°C). In D153G and D153G-I1, metal-binding affinity is lower, and this may account for the loss in thermal stability. DISCUSSION The structure of the active site of AP (11) is shown in Fig. 3 . Residues 407 and 408, between which the epitopes are inserted, are highlighted; the distance from the phosphorus atom to the insertion point (N atom of residue 407) is 15.2 A. If the epitope inserts are assumed to be in an extended-loop conformation, the central residues of the loop would be positioned [20] [21] [22] [23] [24] [25] A from the insertion site and 35-40 A from the phosphate. (Neither the structures of the loops nor their orientation in space is known; they may extend away from the active site, fold into the cleft surrounding the active site, or lie on the surface of the protein.) For comparison, the distance from the phosphorus atom to the atom furthest away from it on the same subunit of the enzyme (the CA atom of residue 1) is 43 A and the distance across the binding domain of an antibody (Fv) is roughly 30-40 A. By considering the distance between the epitope loop and the phosphate-binding site in the active site of the enzyme, it seems likely that the mechanism for modulation involves conformational changes around the active site rather than steric hindrance of substrate. Steric effects due to antibody binding up to 40 A from the active site should be minimal, if there are any. It is worth noting the similarities between residues 101 and 153; both are aspartic acid residues that are symmetrically positioned at approximately equal distances from the phosphate and the insertion point (between aa 407 and 408). In addition, both residues are involved in forming the hydrogen bond network around the active site (formed by residues 101, 166, 153, and 328 *Thirteen-amino acid HIV gpl2O epitope sequence, Ile-Arg-Ile-Gln-Arg-Gly-Pro-Gly-Arg-Ala-Phe-ValThr; 15-aa HCV core epitope sequence, Arg-Lys-Thr-Ser-Glu-Arg-Ser-Gln-Pro-Arg-Gly-Arg-Arg-GlnPro.
tValues determined as described in ref. inhibit or all activate hybrid enzyme activity. Therefore, modulation is not due to how a particular antibody bound to the epitope affects the active site-i.e., a specific contact between the antibody and AP that causes a specific structural change in or near the active site. Inhibition or activation of enzymatic activity of AP-epitope hybrid proteins by anti-epitope antibodies is a general phenomenon. Modulation has been demonstrated with two different epitope inserts and several different mAbs. This demonstrates that modulation of the enzyme activity of the APepitope hybrid proteins is not specific to a particular epitope sequence or to a particular antibody-epitope combination. While the magnitude of modulation varied for the antibodyepitope complexes, all the antibodies inhibited the enzyme activity of the AP-epitope hybrid protein and activated the DiOlS-epitope and D153G-epitope hybrid proteins. The magnitude of change in enzyme activity upon antibody binding may be due in part to the binding affinity of the antibodyepitope complex and the fraction of mAb that is functional.
The AP-epitope hybrid proteins are signaling proteins that detect the presence of an antibody by regulating the level of enzyme activity. We have shown that signaling can be in the form of either an increase or a decrease in enzymatic activity upon formation of the bound antibody complex. The consistent trend of activation or inhibition independent of the amino acid sequence of the inserted epitope and independent of the antibody indicates that modulation is a general phenomenon and should work for many epitope-antibody pairs. As such, the described hybrid system might be useful for homogeneous assays for detection of proteins (12). The observed modulation (2-to 3-fold) should be sufficient for a practical application, since current homogeneous assays exhibit this level of modulation-e.g., enzyme-multiplied immunoassay technique (EMIT) and cloned enzyme donor immunoassay (CEDIA) with digoxin. Engineered signaling proteins may be useful for detecting other macromolecules such as receptors, hormones, and proteins, to tag macromolecules in vivo-e.g., tagging a receptor on a cell surface (13)-and for allosteric regulation of enzymatic function.
